Clinical trials in Pisa – page 30

574 clinical trials in Pisa, Italy across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Pisa at a glance

574

clinical trials

Research sites4

Quick filters

574 trials in Pisa

Open in trial search

Endometrial cancer recurrent

Not recruiting

A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

Registered drugNo placebo

A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Paclitaxel
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Litifilimab
Sponsor:Biogen Idec Research Limited

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Hypocalcaemia

Not recruiting

Study of encaleret compared to standard care in patients with autosomal dominant hypocalcemia type 1

Registered drugNo placebo

Study of encaleret compared to standard care in patients with autosomal dominant hypocalcemia type 1

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Alfacalcidol
Sponsor:Calcilytix Therapeutics Inc.

Contact Research Centre

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Endocrine ophthalmopathy

Not recruiting

Study of AMG 732 injection compared to placebo in patients with moderate to severe thyroid eye disease

Investigational

Study of AMG 732 injection compared to placebo in patients with moderate to severe thyroid eye disease

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:AMG 732
Sponsor:Amgen Inc.

Contact Research Centre

Endocrine ophthalmopathy

Not recruiting

Study of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease

Registered drug

Study of VRDN-001 compared to placebo to evaluate safety and effectiveness in adults with chronic thyroid eye disease

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Viridian Therapeutics Inc.

Contact Research Centre

Cardiac amyloidosis

Not recruiting

Long-term safety study of NNC6019-0001 for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

Registered drugNo placebo

Long-term safety study of NNC6019-0001 for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Novo Nordisk A/S

Contact Research Centre

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Acromegaly

Not recruiting

Study of ALXN2420 with somatostatin analogs for adults with acromegaly to evaluate effectiveness in lowering IGF-1 levels

Registered drug

Study of ALXN2420 with somatostatin analogs for adults with acromegaly to evaluate effectiveness in lowering IGF-1 levels

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:ALXN2420
Sponsor:Alexion Pharmaceuticals Inc.

Contact Research Centre

Bronchopulmonary aspergillosis

Not recruiting

Effectiveness and Safety of Rezafungin in Adults with Chronic Pulmonary Aspergillosis Who Have Limited Treatment Options

Registered drugNo placebo

Effectiveness and Safety of Rezafungin in Adults with Chronic Pulmonary Aspergillosis Who Have Limited Treatment Options

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Rezafungin Acetate
Sponsor:Mundipharma Research Limited

Contact Research Centre

Colitis ulcerative

Not recruiting

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Risankizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Pisa

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Investigating innovative treatments for cardiac conditions and metabolic disorders, with studies focusing on TTR amyloidosis cardiomyopathy and chronic kidney disease management.

Heart Disease Therapeutics
Kidney Disease Management
Hypertension Control

Current trials evaluate novel compounds for improving patient outcomes in cardiac conditions and renal disorders.

02 Oncology Studies

Comprehensive research into various cancer types, including colorectal cancer, gastric cancer, and lung cancer, testing targeted therapies and innovative treatment combinations.

Metastatic Cancer Treatment
Targeted Therapy Development
Immunotherapy Research

Advanced clinical trials exploring breakthrough treatments for multiple cancer types.

03 Autoimmune & Inflammatory Conditions

Studies focusing on chronic inflammatory conditions including Sjögren's Syndrome, psoriatic arthritis, and hidradenitis suppurativa.

Inflammatory Disease Management
Autoimmune Treatment Innovation
Novel Therapeutic Approaches

Evaluating new therapeutic options for improving quality of life in patients with chronic inflammatory conditions.

04 Respiratory & Infectious Diseases

Research into respiratory conditions and infectious diseases, including studies on chronic rhinosinusitis and respiratory syncytial virus infections.

Respiratory Disease Treatment
Infection Management
Vaccine Development

Investigating new approaches to treat and prevent respiratory infections and related conditions.

Back to Italy All countries